CBLL (CeriBell) ROC (Joel Greenblatt) %: -508.83% (As of Mar. 2026)


CBLL CeriBell Inc CBLL
12 GF Score
Price $19.93
! 4 Warning Signs
View Full Analysis

What is CeriBell ROC (Joel Greenblatt) %?

CeriBell CBLL +1.37% 12 ROC (Joel Greenblatt) % is -508.83% as of Mar. 2026. GuruFocus rates CBLL with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, CeriBell ranks worse than 86.56% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CeriBell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -508.83%.

The historical rank and industry rank for CeriBell's ROC (Joel Greenblatt) % or its related term are showing as below:

CBLL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -410.06   Med: -316.26   Max: -262.6
Current: -410.06

During the past 4 years, CeriBell's highest ROC (Joel Greenblatt) % was -262.60%. The lowest was -410.06%. And the median was -316.26%.

CBLL's ROC (Joel Greenblatt) % is ranked worse than
86.56% of 841 companies
in the Medical Devices & Instruments industry
Industry Median: 4.13 vs CBLL: -410.06

CeriBell's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


CeriBell  (NAS:CBLL) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


CeriBell ROC (Joel Greenblatt) % Related Terms


CeriBell ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for CeriBell's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CeriBell ROC (Joel Greenblatt) % Chart

CeriBell Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
-408.63 -262.60 -278.94 -353.57

CeriBell Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -312.82 -372.55 -415.85 -395.44 -508.83

CBLL vs BBNX, SIBN, TCMD: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, CeriBell's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CeriBell ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CeriBell's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where CeriBell's ROC (Joel Greenblatt) % falls into.


CBLL
12GF Score
CeriBell Inc CBLL
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CeriBell ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.053 + 7.288 + 5.116) - (10.08 + 0.101 + 7.904)
=9.372

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.712 + 6.902 + 5.113) - (11.817 + 0.088 + 3.138)
=12.684

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of CeriBell for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-77.212/( ( (4.326 + max(9.372, 0)) + (3.967 + max(12.684, 0)) )/ 2 )
=-77.212/( ( 13.698 + 16.651 )/ 2 )
=-77.212/15.1745
=-508.83 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -508.83% mean?
CeriBell (CBLL) has a ROC (Joel Greenblatt) % of -508.83% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CeriBell and its competitors. According to the industry distribution chart, CeriBell ranks #728 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is CeriBell's ROC (Joel Greenblatt) % too high?
CeriBell's current ROC (Joel Greenblatt) % is -508.83%. Based on the distribution chart, CeriBell ranks #728 out of 841 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CeriBell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CeriBell's ROC (Joel Greenblatt) % compare to BBNX and SIBN?
According to the Medical Devices & Instruments industry distribution chart, CeriBell ranks #728 out of 841 companies for ROC (Joel Greenblatt) %. This places CeriBell in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.13, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CeriBell and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CeriBell's current ROC (Joel Greenblatt) % is -508.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CeriBell stock overvalued right now?
CeriBell (CBLL) has a current ROC (Joel Greenblatt) % of -508.83%. The current ROC (Joel Greenblatt) % is -508.83%. CeriBell's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CeriBell (CBLL), the current ROC (Joel Greenblatt) % is -508.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CeriBell Business Description

Address 360 N. Pastoria Avenue, Sunnyvale, CA, USA, 94085
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
12GF Score

Get the complete analysis for CBLL

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.93
Price